NDA 021853 · Reliant Pharms
Omacor
Omega-3acid Ethyl Esters · Oral
Last checked: Nov 19, 2026Latest source record: Jun 12, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jun 12, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OMACOR · OMEGA-3ACID ETHYL ESTERS 1G · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omega-3acid Ethyl Esters" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Randomized, Open-Label, Single-Dose, Crossover Study of the Comparative Bioavailability of EPA and DHA in a Novel Liquid Crystalline Nanoparticle-Based Formulation of ω-3 Acid Ethyl Ester Versus Omacor® Soft Capsule among Healthy Adults.
Kang KM, Jeon SW, De A, et al. · Int J Mol Sci 2023 · Randomized Controlled Trial
- The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Manson JE, Bassuk SS, Lee IM, et al. · Contemp Clin Trials 2012 · Comparative Study, Multicenter Study
- Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.
Sheridan DA, Bridge SH, Crossey MM, et al. · Liver Int 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome.
Babinets LS, Melnyk NA, Shevchenko NO, et al. · Wiad Lek 2018 · Controlled Clinical Trial
- Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L, Scorletti E, Curzen N, et al. · Atherosclerosis 2016 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Update on the Vitamin D and OmegA-3 trial (VITAL).
Pradhan AD, Manson JE · J Steroid Biochem Mol Biol 2016 · Randomized Controlled Trial
Sponsor: Reliant Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.